Published in Support Care Cancer on July 19, 2007
A Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer | NCT02382315
Patient-clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. Patient Educ Couns (2009) 1.34
Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer (2012) 0.97
Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. BJU Int (2012) 0.95
Conquer fear: protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence. BMC Cancer (2013) 0.94
Illness cognitions in head and neck squamous cell carcinoma: predicting quality of life outcome. Support Care Cancer (2009) 0.93
Social-cognitive processes associated with fear of recurrence among women newly diagnosed with gynecological cancers. Gynecol Oncol (2012) 0.89
Changes in sexual roles and quality of life for gay men after prostate cancer: challenges for sexual health providers. J Sex Med (2014) 0.88
Breast cancer treatment decision making among Latinas and non-Latina Whites: a communication model predicting decisional outcomes and quality of life. Health Psychol (2012) 0.87
Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. Ann Surg (2016) 0.85
Evolving Information Needs among Colon, Breast, and Prostate Cancer Survivors: Results from a Longitudinal Mixed-Effects Analysis. Cancer Epidemiol Biomarkers Prev (2015) 0.81
Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ (2014) 0.80
Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer. BMC Cancer (2016) 0.79
Cancer Survivorship Care: Summarizing the 6 Tools for Success. Fed Pract (2011) 0.79
Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiat Oncol (2015) 0.78
Men with prostate cancer over the first year of illness: their experiences as biographical disruption. Support Care Cancer (2009) 0.77
Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant (2014) 0.77
Fear of Cancer Recurrence and its Predictive Factors among Iranian Cancer Patients. Indian J Palliat Care (2014) 0.77
Cancer as biographical disruption: constructions of living with cancer. Support Care Cancer (2011) 0.76
Prevalence and correlates of fear of recurrence among adolescent and young adult versus older adult post-treatment cancer survivors. Support Care Cancer (2016) 0.75
A qualitative exploration of fear of cancer recurrence (FCR) amongst Australian and Canadian breast cancer survivors. Support Care Cancer (2015) 0.75
Health behaviours and fear of cancer recurrence in 10 969 colorectal cancer (CRC) patients. Psychooncology (2016) 0.75
Fear of recurrence: the importance of self-efficacy and satisfaction with care in gay men with prostate cancer. Psychooncology (2014) 0.75
Fear of cancer recurrence and its predictors among cervical cancer survivors. J Gynecol Oncol (2017) 0.75
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology (1996) 3.26
Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology (2006) 2.55
The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med (2003) 1.91
Uncertainty in illness. Image J Nurs Sch (1988) 1.67
Fear of cancer recurrence--a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology (1997) 1.65
The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer (2005) 1.59
Doctor-patient communication and cancer patients' quality of life and satisfaction. Patient Educ Couns (2000) 1.50
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am (1993) 1.45
A population-based study of the quality of life of cancer survivors and their family caregivers. Cancer Nurs (2006) 1.29
Watching, waiting and uncertainty in prostate cancer. J Clin Nurs (2007) 1.28
Confidence in the ability to communicate with physicians among low-income patients with prostate cancer. Urology (2004) 1.19
'Satisfaction with care': associations with health-related quality of life and psychosocial function among Swedish patients with endocrine gastrointestinal tumours. Eur J Cancer Care (Engl) (2002) 1.16
An instrument to measure patient satisfaction with healthcare in an observational database: results of a validation study using data from CaPSURE. Am J Manag Care (2000) 1.14
Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs (2004) 1.11
Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Psychosomatics (2006) 1.10
Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol (2003) 1.06
Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum (2003) 1.03
Fear of recurrence and possible cases of anxiety and depression in orofacial cancer patients. Int J Oral Maxillofac Surg (2003) 1.01
Uncertainty in prostate cancer. Ethnic and family patterns. Cancer Pract (1998) 0.95
Breast cancer survivors: an exploration of quality of life issues. Cancer Nurs (1993) 0.81
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89
Urology resident publication output and its relationship to future academic achievement. J Urol (2010) 1.85
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol (2007) 1.70
Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol (2010) 1.70
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int (2013) 1.61
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A (2008) 1.61
Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology (2013) 1.59
Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology (2004) 1.58
The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57
Cumulative cost pattern comparison of prostate cancer treatments. Cancer (2007) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol (2012) 1.56
Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol (2013) 1.55
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52